CV 9103 / CureVac - LARVOL DELTA

Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next. (PubMed, NPJ Vaccines) - "We discuss their mechanism of action, advantages in production and safety, and results from early clinical trials (e.g., CV9103/4). Key challenges like antigen selection and the immunosuppressive tumor microenvironment are addressed, alongside advancements in lipid nanoparticle delivery and combinatorial strategies with checkpoint inhibitors to enhance efficacy and usher in personalized PC treatment."

Journal • Review • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) (ESMO 2017) - "Safety and immune responses to the predecessor therapy CV9103 encoding 4 of the antigens have been described previously. CV9104 did not improve OS compared to placebo. Additional clinical outcomes and analyses of cellular and humoral immune responses will be presented and impact on further development will be discussed."

Clinical • P1/2 data • Prostate Cancer